

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	27.5	116.3	(79.6-164.2)	Male	18	18.2	98.9	(58.6-156.4)
Female	11	11.1	99.0	(49.3-177.1)	Female	19	14.9	127.3	(76.6-198.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.3	151.6	(65.3-298.8)	Male	8	4.6	175.0	(75.3-344.8)
Female	1	4.7	nc	(nc-nc)	Female	5	4.0	125.9	(40.6-293.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	18	15.6	115.2	(68.2-182.1)
Female	108	108.5	99.5	(81.6-120.1)	Female	14	14.1	99.6	(54.4-167.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	7	10.8	64.6	(25.9-133.2)
<u>Colon / Rectum</u>					Female	6	5.5	108.7	(39.7-236.5)
Male	28	32.8	85.4	(56.7-123.4)	<u>Ovary</u>				
Female	33	35.8	92.2	(63.5-129.5)	Female	5	10.5	47.7	(15.4-111.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.3	68.4	(22.0-159.6)	Male	9	8.9	101.4	(46.3-192.5)
Female	3	2.3	nc	(nc-nc)	Female	11	10.5	104.7	(52.2-187.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	103	107.6	95.8	(78.2-116.1)
Female	4	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.3	110.3	(44.2-227.3)
Male	17	15.0	113.5	(66.1-181.7)	Female	6	4.1	144.8	(52.9-315.1)
Female	8	9.3	86.0	(37.0-169.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.9	126.8	(40.9-296.0)
Male	2	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	8	6.0	133.6	(57.5-263.3)
<u>Leukemia</u>					Female	18	18.6	97.0	(57.5-153.4)
Male	14	9.8	142.6	(77.9-239.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	8.1	73.9	(27.0-160.8)	Female	28	24.9	112.7	(74.8-162.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	7.9	126.4	(60.5-232.4)	Male	388	374.2	103.7	(93.6-114.6)
Female	1	2.9	nc	(nc-nc)	Female	386	385.2	100.2	(90.5-110.7)
<u>Lung and Bronchus</u>									
Male	56	51.8	108.0	(81.6-140.3)					
Female	53	57.2	92.6	(69.3-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;